Quick Answer
Royalty Pharma plc reported Earnings Per Share Diluted of $1.78 per share for the year ending 2025.
- Royalty Pharma plc showed a decrease of -6.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Royalty Pharma plc's annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.09 per share | Q3 2020: $0.79 per share | Q1 2021: $0.18 per share | Q2 2021: $1.08 per share | Q3 2021: $0.24 per share | Q1 2022: $0.12 per share | Q2 2022: $0.70 per share | Q3 2022: $0.32 per share | Q1 2023: $0.76 per share | Q2 2023: $0.50 per share | Q3 2023: $0.16 per share | Q1 2024: $0.01 per share | Q2 2024: $0.23 per share | Q3 2024: $1.21 per share | Q1 2025: $0.55 per share | Q2 2025: $0.07 per share | Q3 2025: $0.67 per share.
- Over the full 6 years of available data (2020 to 2025), Royalty Pharma plc's Earnings Per Share Diluted has grown by 34.8%.
- Historical annual values: Fiscal year 2025: $1.78 per share | Fiscal year 2024: $1.91 per share | Fiscal year 2023: $2.53 per share | Fiscal year 2022: $0.10 per share | Fiscal year 2021: $1.49 per share | Fiscal year 2020: $1.32 per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: